drugset / Trial / NCT04238416

Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF

NCT04238416

RandomizedParallel-groupOpen-labelTreatment

Summary

This study analyses the effect of intravenous branched chain amino acids (BCAA) on overt HE in patients with ACLF. The investigators plan to study the efficacy of combining intravenous BCAA with lactulose versus lactulose alone in the medical management of overt HE in patients with ACLF and its impact on overall survival and improvement in grade of HE.

Timeline

Start
2019-11-01
Primary completion
2021-12-30
Completion
2021-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject amino acids Unknown Intravenous
Subject isoleucine Other / unclassified Intravenous
Subject valine Other / unclassified Intravenous
Background Lactulose Other / unclassified Oral